Biovica
Dag Hammarskjölds väg 54B
Uppsala Science Park
Uppsala
752 37
Tel: 46-0-18-44-44-830
Fax: 46-0-18-57-24-28
Website: http://biovica.com/
Email: info@biovica.com
About Biovica
Biovica is a biotech company founded in 2009, focused on providing biomarkers and tools to better evaluate cancer therapies and predict treatment response. Biovica aim to contribute to personalized healthcare and better outcome for cancer patients by improved evaluation of therapy response and minimizing overtreatment.YEAR FOUNDED:
2009
LEADERSHIP:
CEO: Anders Rylander
77 articles about Biovica
-
DiviTum(R) TKa Results to be Presented at ASCO
6/1/2023
Biovica, active in cancer diagnostics, announces that a poster with DiviTum® TKa results from the SWOG study S0226 will be presented at the the world's largest cancer conference, the annual ASCO meeting, on Sunday, June 4.
-
Announcement from Biovica International AB's Extra General Meeting
5/17/2023
Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) The extra general meeting of Biovica International AB was held today on 17 May 2023 and the following resolutions were passed by the meeting.
-
Biovica Signs the First Commercial Agreement for DiviTum(R) TKa in US
5/17/2023
Biovica announces that Biovica Inc, the US laboratory and subsidiary of Biovica International AB, has signed a provider contract with MediNcrease Health Plans, a US, national provider network and provider advocacy firm, to make Biovica's blood test DiviTum® TKa available to the more than 15 million lives served by Clients and Payers of MediNcrease.
-
Notice of Extra General Meeting in Biovica International AB - April 27, 2023
4/27/2023
Biovica International The shareholders of Biovica International AB, reg. no. 556774-6150, are hereby invited to the extra general meeting to be held on Wednesday 17 May 2023, at 13.00 CET at Baker & McKenzie Advokatbyrå's premises at Vasagatan 7 in Stockholm.
-
Biovica establishes DiviTum(R) TKa Commercialization Partnership in Italy
4/4/2023
Biovica International Biovica, active in cancer monitoring, announces that the company has signed a commercial partnership agreement with the Italian company, IT Health Fusion, for the commercialization of the DiviTum® TKa assay in Italy.
-
Biovica signs DiviTum(R) TKa Commercial Partner Agreement for Dutch and Polish Markets
3/28/2023
Biovica, active in cancer monitoring, announces that the company has signed a commercial partnership with the European distributor TOROMEDICAL group for the commercialization of the DiviTumTKa test for clinical routine use in the Netherlands and Poland.
-
Q3 Interim Report November -January 2022/2023
3/16/2023
Biovica International DiviTum® TKa ready for clinical use in the US
-
Nomination Committee for Biovica for the 2023 Annual General Meeting
3/13/2023
Biovica International The Nomination Committee prior to the 2023 Annual General Meeting will consist of three members, who shall represent the two shareholders with the highest number of shares who accept the assignment to be part of the Nomination Committee as of December 31, 2022, and the Chairman of the Board.
-
Biovica Receives CLIA Certification
2/8/2023
Biovica International Biovica, active in cancer monitoring, announces that the company's test laboratory in San Diego, California, has received CLIA certification allowing Biovica to begin commercial sales of DiviTum® TKa on the US market.
-
DiviTum(R) TKa Clinical Validation Data Published in Biomarkers
1/31/2023
Biovica International Biovica, active in cancer diagnostics, announces that results clinically validating the DiviTum® TKa assay have been published in the scientific journal Biomarkers.
-
Q2 Interim Report August-October 2022/2023
12/15/2022
Biovica International Successful capital acquisition paves the way for launch in the USA
-
Biovica Establishes Experienced US Sales Team
12/1/2022
Biovica International Biovica, active in cancer diagnostics, announces that the company has employed a sales team of total of eight people to secure a fast and smooth launch and the further commercial development of DiviTum® TKa on the US market.
-
Biovica Appoints Anders Morén as CFO
10/20/2022
Biovica International Biovica, active in cancer diagnostics, announces that Anders Morén has been appointed as the company's Chief Financial Officer.
-
Biovica Submits CLIA Lab Application for DiviTum(R)TKa Launch
10/19/2022
Biovica International Biovica announces that the company has submitted its CLIA lab application, marking yet another significant milestone for the US commercial launch of the recent FDA cleared test DiviTum®TKa.
-
Notice of Extra General Meeting in Biovica International AB - October 18, 2022
10/18/2022
Biovica International The shareholders of Biovica International AB, reg. no. 556774-6150, are hereby invited to the extra general meeting to be held on Monday 7 November 2022, at 13.00 CET at Baker & McKenzie Advokatbyrå's premises at Vasagatan 7 in Stockholm.
-
Q1 Interim Report May-July 2022/2023 - DiviTum(R)TKa Approved for Launch in the US
8/31/2022
During the quarter, we reached one of the most important milestones in Biovica's history when the US Food and Drug Administration granted market approval for our assay, DiviTum®TKa, as a tool for monitoring disease progression in post-menopausal women with hormone receptor positive metastatic breast cancer.
-
Announcement from Biovica International AB's annual general meeting
8/31/2022
Biovica International The annual general meeting of Biovica International AB was held on 31 August 2022 and the following resolutions were passed by the meeting.
-
Biovica invites to market update on 18 August 15.00 - Bringing DiviTum(R)TKa to US patients
8/15/2022
Biovica, active in cancer diagnostics, is hosting a market update due DiviTum®TKa's US market approval received on July 29 from the US Food and Drug Administration.
-
Biovica Receives FDA Approval for DiviTum(R)TKa
7/30/2022
Biovica, active in cancer diagnostics, announces that FDA has granted 510 clearance for the product DiviTum®TKa as an aid in monitoring disease progression in previously diagnosed hormone receptor positive, metastatic postmenopausal female breast cancer patients.
-
Notice of Annual General Meeting in Biovica International AB
7/27/2022
The shareholders of Biovica International AB, reg. no. 556774-6150, are hereby invited to the annual general meeting on Wednesday 31 August 2022.